Tag Archives: Medicare
By Guest Blogger | Published: March 19, 2013
by Tom Norton As the US pharmaceutical industry anxiously watches the rapid onset of Obamacare, certainly one of the more pressing issues is the debate over the number of drugs that will be reimbursed in each therapeutic class under the Essential Health Benefits (EHB) program. To say that this is a critical concern for the future [...]
By Jill Wechsler | Published: February 20, 2013
Jill Wechsler Blog – PE Feb. 22, 2013 Part D Politics: Medicare drug rebates or price controls? While health care was barely mentioned in the recent State of the Union address, President Obama generated some interest in his proposal to cut Medicare spending by reducing “taxpayer subsidies to prescription drug companies.” That’s code for requiring pharma marketers to pay [...]
By Guest Blogger | Published: February 1, 2013
by Tom Norton This past week or so, with Obamacare’s start up less than a year away, we have been treated to several entertaining vignettes as the nation’s governors begin to wrestle with the realities of the new healthcare law.
By Jill Wechsler | Published: January 28, 2013
In the dog-eat-dog world of federal deficit reduction, there seems to be one health-related spending cut with broad bi-partisan support: require drug companies to give the federal government “a better deal on medications for low-income people on Medicare.” Nearly 70% of respondents back this strategy, according to a survey sponsored by the Kaiser Family Foundation [...]
By Guest Blogger | Published: November 7, 2012
by Tom Norton With the Presidential election decided and President Obama the clear winner, it’s time for Pharma to get down to business on the implementation of ObamaCare. Here are some of the key actions to anticipate between now and January 1, 2013.